• NIH funds mechanistic research, not drug development
• Major investments from venture and pharma require de-risking through late preclinical/early clinical stage

Solution

We will leverage creative and innovative funding mechanisms that bridge the valley of death through venture philanthropy, NIH funding of early clinical studies, early venture investments (angel-like), and early nonexclusive engagement with pharmaceutical industry; GMP manufacturing capabilities exist at UMass Chan for small POC trials with targeted siRNA.

The AITI has raised the amounts shown below (>$10M, >$100M)